← Latest news 
Oxford and Serum partner on next malaria vaccine R78C aiming better parasite stage coverage
Science
Published on 28 April 2026

Aiming shots at malaria as it changes stages
Oxford University has struck a new collaboration with Serum Institute of India to develop malaria vaccine R78C. The plan targets multiple stages of the malaria parasite to improve effectiveness, while Serum will produce the vaccine at scale. With malaria burden highest across sub Saharan Africa, the pact could accelerate access to a more potent option.
- Oxford and Serum Institute are co-developing malaria vaccine R78C
- The vaccine targets different stages of the malaria parasite
- Serum Institute will manufacture it at large scale
- Development focuses on major malaria impact across sub Saharan Africa
Read the full story at The Economic Times
This summarization was done by Beige for a story published on
The Economic Times
